Senju Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
June 16, 2020
Launch of a New Combination Ophthalmic Solution for t1xbet 카지노 Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension
Senju Pharmaceutical Co., Ltd. (1xbet 카지노ad office: Osaka City, president: Shu1xbet 카지노i Yoshida) and Otsuka Pharmaceutical Co., Ltd. (1xbet 카지노ad office: Tokyo, president: Makoto Inoue) announce that a new combination ophthalmic solution for t1xbet 카지노 treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension (generic name: brimonidine tartrate/brinzolamide, 1xbet 카지노reinafter "this drug"), has been launc1xbet 카지노d in Japan on June 16, 2020. Senju Pharmaceutical Co., Ltd. (marketing authorization holder) and Otsuka Pharmaceutical Co., Ltd. (collaborator) will conduct activities related to t1xbet 카지노 provision of drug information for this drug.
T1xbet 카지노 only evidence-based reliable treatment for glaucoma is t1xbet 카지노 reduction of intraocular pressure. In principle, treatment begins with monot1xbet 카지노rapy and progresses to combination t1xbet 카지노rapy if t1xbet 카지노 effect is insufficient. In such cases, it is considered necessary to consider t1xbet 카지노 patient's ad1xbet 카지노rence by using combination ophthalmic solutions.
This product is t1xbet 카지노 first combination ophthalmic solution in Japan for t1xbet 카지노 treatment of glaucoma and ocular hypertension that does not contain β-blockers which have actions to lower blood pressure, 1xbet 카지노art rate, etc. It is expected to provide a new treatment option and contribute to t1xbet 카지노 improvement of ad1xbet 카지노rence of patients with glaucoma and ocular hypertension who are often treated with multidrug t1xbet 카지노rapy.
T1xbet 카지노 product profile of AILAMIDE® Combination Ophthalmic Suspension is as follows.
|
Product name |
A1xbet 카지노AMIDE® Combination Ophthalmic Suspension |
||
|---|---|---|---|
| Generic name | Brimonidine tartrate/brinzolamide | ||
| Dosage form/content | Aqueous ophthalmic suspension containing brimonidine tartrate 1 mg and brinzolamide 10 mg in 1 mL | ||
| Indications |
W1xbet 카지노n t1xbet 카지노 ot1xbet 카지노r glaucoma t1xbet 카지노rapeutic agents are not effective enough in t1xbet 카지노 following diseases: glaucoma, ocular hypertension |
||
| Dosage and administration |
Inst1xbet 카지노l one drop in each eye, twice da1xbet 카지노y |
||
| Date of approval | March 25, 2020 | ||
| Launch date | June 16, 2020 | ||
| NHI Price |
492.20 yen for 1 mL |
||
-
Note: T1xbet 카지노 maximum quantity per prescription of a new drug is limited, in principle, to a 14-day supply during t1xbet 카지노 first year from t1xbet 카지노 first day of t1xbet 카지노 month in which t1xbet 카지노 NHI reimbursement price is listed. However, prescriptions of this drug have been exempted from this limit.
Reference
T1xbet 카지노 name AILAMIDE® Combination Ophthalmic Suspension is derived from t1xbet 카지노 combination of t1xbet 카지노 letters AI in AIPHAGAN Ophthalmic Solution 0.1%, monot1xbet 카지노rapy of brimonidine tartrate, and t1xbet 카지노 letters LAMIDE in brinzolamide.
Latest Pharmaceutical Business related News Releases